6-Bromo-8-iodo-2-methylimidazo[1,2-a]pyridine

Catalog No. :
ACQMYZ925
CAS No. :
1421601-69-5
Molecular Formula :
C8H6BrIN2
Molecular Weight :
336.96

IUPAC Name:6-bromo-8-iodo-2-methylimidazo[1,2-a]pyridine

6-Bromo-8-iodo-2-methylimidazo[1,2-a]pyridine structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$130.00Login to see priceIn stockInquiry
250mg97%$217.00Login to see priceIn stockInquiry
500mg97%$309.00Login to see priceIn stockInquiry
1g97%$464.00Login to see priceInquiryInquiry
5g97%$1391.00Login to see priceInquiryInquiry
10g97%$2322.00Login to see priceInquiryInquiry
25g97%$4643.00Login to see priceInquiryInquiry
50g97%$7430.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name6-Bromo-8-iodo-2-methylimidazo[1,2-a]pyridine
IUPAC Name6-bromo-8-iodo-2-methylimidazo[1,2-a]pyridine
MDL No.MFCD22391931
Molecular FormulaC8H6BrIN2
Molecular Weight336.96
SMILESCC1=CN2C=C(Br)C=C(I)C2=N1
InChI KeyZTPQJTYRQYARJK-UHFFFAOYSA-N
Synonym6-bromo-8-iodo-2-methylimidazo[1,2-a]pyridine | 1421601-69-5 | 6-bromo-8-iodo-2-methyl-imidazo[1,2-a]pyridine | MFCD22391931 | SCHEMBL24387034 | AKOS026728844 | AS-79132 | SY251311 | EN300-105782 | P19434
CAS No.1421601-69-5
PubChem CID71755923

Synthetic Route by SureRoute

1. ACQMYZ925 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACQMYZ925 route product structure diagram
    ACQMYZ9251421601-69-5 In Stock
Inquiry

2. ACQMYZ925 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACQMYZ925 route product structure diagram
    ACQMYZ9251421601-69-5 In Stock
Inquiry

Comments (0)